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The hepatitis B virus core (HBc) virus-like particle (VLP) is known as one of the most immunogenic antigens
and carrier vehicles in different immunization strategies. Recent findings are suggesting the potential of the
HBc VLPs as an oral immunogen. Here, we focus on the induction of serum humoral responses by oral
administration of HBc VLPs in preparations substantially free of lipopolysaccharide and immunomodulating
encapsidated RNA. The full-length HBc antigen was used, because the C-terminal arginine-rich tail may
contribute to the immunogenicity of the antigen as the region is involved in cell surface heparan sulfate binding
and internalization of the protein. Serum antibody levels and isotypes were determined following oral admin-
istration of the HBc VLPs with the perspective of using the HBc VLP as an immunostimulatory and carrier
molecule for epitopes of blood-borne diseases in oral immunization vaccination strategies. Following oral
administration of the HBc VLP preparations to mice, a strong serum humoral response was induced with
mainly immunoglobulin G2a (IgG2a) antibodies, pointing toward a Th1 response which is essential in the
control of intracellular pathogens. Intraperitoneal immunization with the HBc VLP induced a stronger, mixed
Th1/Th2 response. Finally, a comparison was made with the induced serum humoral response following oral
administration of the recombinant cholera toxin B pentamer, a commonly used oral immunogen. These
immunizations, in contrast, induced predominantly antibodies of the IgG1 isotype, indicative of a Th2 re-
sponse. These data suggest that the HBc VLP can be an interesting carrier molecule in oral vaccine
development.
The hepatitis B virus core (HBc) virus-like particle (VLP) is
a strong immunogen that is remarkably tolerant to substitu-
tions, insertions, and deletions in its two immunodominant
loop regions and its C-terminal tail (28, 30, 31, 45, 53, 54). The
VLP is also capable of transferring its immunogenic capacities
to these additions and is therefore often used as a vehicle for
foreign B- and T-cell epitopes. With the HBc carrier platform,
protective immunity could be induced against a range of patho-
gens, including several Plasmodium spp. (43, 56, 57), the influ-
enza A virus (48), and the Puumala hantavirus (64).
Fifis et al. (15) suggested that the strong immunogenicity of
VLPs is based on their size, which is suitable for uptake by
dendritic cells, thereby directly promoting dendritic cell mat-
uration and migration, a process essential for the stimulation
of an immune response (15, 17). In addition, some VLPs that
resemble infectious viruses retain their receptor binding re-
gions and are able to target and enter cells by using their
normal receptor (21). For HBc VLPs, a specific role for the
arginine-rich C-terminal tail in cell surface heparan sulfate
binding and uptake has been demonstrated (8, 9, 66). Further-
more, HBc VLPs are generally known to be extremely stable as
they are resistant to denaturing agents and variations in pH
(between 2 and 13) and temperature (1 h at 70°C) (3, 49),
which makes them suitable for use as oral immunogens. It has
been shown that recombinant Norwalk VLPs (2) and hepatitis
E VLPs (36) are at least partially resistant to degradation in
the gastrointestinal tract and thus able to induce mucosal and
systemic immune responses following oral delivery. In such a
case, the mucosal response can provide a first barrier in pre-
venting viral infection. After oral vaccination of mice with
human papillomavirus-like particles, it was demonstrated, us-
ing an in vitro assay, that systemic virus-neutralizing antibodies
could be induced, though the systemic (immunoglobulin G
[IgG]) immune response against these orally delivered parti-
cles was rather weak (36, 55). Moreover, it is generally known
that when VLPs are used as a carrier platform, the response
against the integrated epitopes is weaker than the VLP-in-
duced response. Therefore, there is a need to screen for VLPs
that induce a high systemic humoral response after oral vacci-
nation. These VLPs, used as a carrier platform, would still be
able to induce a strong systemic response against integrated
epitopes. As the HBc VLP is known as one of the most im-
munogenic and stable VLPs (46) and as recent findings suggest
the potential of the HBc VLP as an oral immunogen (37), we
investigated whether this particle, following oral administra-
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tion, can induce a serum humoral response of a potentially
protective level. Because the C-terminal arginine-rich region
might contribute to the immunogenicity of the VLP, the full-
length protein was used. Immunostimulating contaminants,
such as LPS and incorporated RNA, were extracted from the
preparations during purification. The strength and nature of
the serum humoral response in mice were determined follow-
ing four gavages with 50 g recombinant HBc (rHBc) and
compared to those observed after intraperitoneal (i.p.) immu-
nization with the VLPs. In addition, the induced antibody
levels and isotypes were compared to those observed following
oral immunization with the recombinant cholera toxin B sub-
unit (rCTxB), a frequently used oral immunogen (for reviews,
see references 11 and 68).
MATERIALS AND METHODS
Expression and purification of the rHBc VLPs. The molecular cloning of the
HBc gene (no. LMBP 2470; collection, University of Ghent, Belgium), the
expression of full-length HBc particles in Escherichia coli and the purification of
the rHBc VLPs were described previously by Broos et al. (6). The purity and
identity of the samples were evaluated on 12.5% sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) gels and on Western blots. The
correct particle assembly was ascertained by electron microscopy after negative
staining using 1% phosphotungstic acid and ultracentrifugation on a linear su-
crose gradient. Purified protein samples were dialyzed overnight against phos-
phate-buffered saline (PBS) before administration to mice.
Plasmid construction, expression, and purification of the CTxB. To express
CTxB in E. coli, we used the ctxB gene, which was designed according to the
codon usage by E. coli (1). The gene was kindly provided by Paulo Lee Ho
(Centro de Biotecnologia, Instituto Butantan, Sa˜o Paulo, Brazil). CTxB was
secreted in the periplasm of E. coli cells, allowing intramolecular disulfide bridge
formation, essential for efficient folding (and pentamerization) and, conse-
quently, efficient binding of the toxin to the GM1 receptor (38). To achieve
secretion, the ctxB gene was fused to the secretion signal coding sequence of E.
coli outer membrane protein A (sOmpA), as described by Guisez et al. (23).
Briefly, bacteria were allowed to grow at 37°C until an optical density at 600 nm
of 0.5 was reached and induction of the CTxB occurred in the absence of IPTG
(isopropyl--D-thiogalactopyranoside) at 28°C. Periplasmatic proteins were ex-
tracted by osmotic shock. The periplasmatic protein mixture was extracted in 20
mM Tris (pH 7.4) and 20 mM NaCl and loaded on a DEAE-Sephacel column
(Amersham Biosciences). Retained proteins were eluted from the column by
using a gradient of increasing NaCl: most of the CTxB was recovered at 125 mM
NaCl. This fraction was diluted 1/5 in 20 mM Tris (pH 7.4) and loaded on a
HiTrap SP FF column (1 ml; GE Healthcare) by using an A´kta chromatographic
purification platform. After elution using a linear NaCl gradient from 20 mM to
1 M NaCl in 20 mM Tris (pH 7.4), CTxB was found as a single peak at 400 mM
NaCl. The purity of the recombinant protein was analyzed on a 15% SDS-PAGE
gel with a Bio-Rad Protean II system (Bio-Rad) according to Laemmli (32). Gels
were stained with Coomassie brilliant blue G-250 or silver stained (SilverQuest
silver stain kit; Invitrogen). For CTxB, a monomeric protein band of 13 kDa was
expected. The identity of the protein was determined by Western blot analysis,
using goat anti-CTxB (1/2,000; List Biological Laboratories, Inc.) and horserad-
ish peroxidase (HRP)-labeled human anti-goat as the secondary antibody (1/
2,000; immunodetection kit; Invitrogen). Pentamerization of the CTxB mono-
mers was shown with SDS-PAGE by loading nonboiled protein samples in
2-mercaptoethanol free loading dye (35). Protein concentrations were deter-
mined using the Bradford assay (5).
Administration of the rHBc VLP and rCTxB pentamers to mice. For oral
immunization with HBc, two groups of six 8-week-old BALB/c BY Jico mice
(Charles River Laboratories, France) were adapted to conditions in a dedicated
animal house. To one group of mice, 50 g of purified rHBc in PBS was
administered intragastrically by gavage. This was repeated four times: on days 0,
13, 24, and 48. An administered volume of 300 l liquid was not exceeded. The
control group received an equal volume of PBS. For oral vaccination with CTxB,
two groups of six 8-week-old mice were orally immunized with 50 g purified
recombinant CTxB at the same time points. For i.p. injection of HBc, one group
of six mice received 10 g HBc antigen (HBcAg) i.p. at days 0, 13, and 24, while
another group was injected with PBS as a negative control.
Sample collection. Blood samples were obtained from mice orally immunized
with HBc by tail bleeding on days 0, 16, 42, 62, and 72 and by heart puncture on
day 106. Similarly, blood samples were taken from i.p.-injected mice on days 0
and 36 and from mice orally immunized with CTxB on days 0 and 62. Samples
were kept on 37°C for 30 min and centrifuged twice at 9,000  g for 15 min to
collect the serum. Samples were stored at 20°C until testing.
Antibody ELISA. Serum HBc-specific antibody levels were determined by a
sandwich enzyme-linked immunosorbent assay (ELISA) as described by Broos et
al. (6), making a serial twofold dilution of the serum samples. For characteriza-
tion and isotyping of the humoral response, HRP-conjugated goat anti-mouse
IgG, IgA, IgG1, IgG2a, and IgG2b were obtained from Zymed Laboratories (San
Francisco, CA) (1/2,000), and HRP-conjugated goat anti-mouse IgG3 was ob-
tained from Centaur BVBA (Brussels, Belgium). After addition of the enzyme
substrate, the absorbance was measured at 492 nm and 630 nm (background)
(UltraMicroplate Reader ELx808; Bio-Tek Instruments, Inc.). The data were
analyzed by Student’s t test (P  0.05). When pooled serum fractions were
analyzed, the samples were considered to be reactive when the measured absor-
bance at 492 nm was two and a half times higher than the negative control
absorbance at the same dilution.
Serum CTxB-specific antibody levels were determined in an ELISA, based on
the method described by Fingerut et al. (16). Briefly, ELISA plates were incu-
bated overnight at 4°C with 100 l of 15 g/ml GM1 (monosialoganglioside
GM1; Sigma) in bicarbonate buffer (pH 9.5). Blocking was performed with 1%
bovine serum albumin in PBS-0.2% Tween 20. Purified CTxB at a concentration
of 20 g/ml in 1% bovine serum albumin in PBS-0.2% Tween 20 was allowed to
bind to the receptor for 1 h at 37°C. Twofold serum dilutions were added and
incubated for 2 h at 37°C. The presence of serum CTxB-specific antibodies was
shown using HRP-conjugated goat anti-mouse IgG following oxidation of the
added o-phenylenediamine substrate.
RESULTS
Characterization of rHBc VLPs and rCTxB. rHBc VLPs
from E. coli were purified, and protein samples were analyzed
on a 12.5% SDS-PAGE gel and a Western blot (Fig. 1A and
B). The HBc monomer was observed as a 21-kDa band; mul-
timeric complexes appeared as higher-molecular-mass bands.
Examination of these preparations by electron microscopy re-
vealed the presence of a large number of well-assembled par-
ticles (data not shown).
Quantification of periplasmatically expressed and purified
CTxB revealed that our two-step purification protocol yields 2
mg CTxB from 1 liter culture. Periplasmatic secretion is ap-
propriate since periplasmatic chaperones (58) and thiol-disul-
fide oxidoreductase (disulfide bridge formation) carry out ef-
FIG. 1. Analysis of the purified HBc protein samples on a Coomas-
sie brilliant blue-stained 12.5% SDS-PAGE gel (A) and a Western blot
(B). (A) Lane 1, LMW protein mixture (Amersham Biosciences); lane
2, purified HBcAg. The HBc monomer at 21 kDa is indicated by an
arrow. Multimeric structures appear as higher protein bands. (B) Lane
2, Western blot analysis of the purified HBcAg.
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ficient folding and assembly of the different subunits (47, 71),
leading to the formation of a completely functional CTxB
pentamer complex. The purity of the recombinant proteins and
their pentameric nature were analyzed on an SDS-PAGE gel
(Fig. 2A) and a Western blot: the goat anti-CTxB antibody
recognized the protein bands at 13 and 50 kDa (Fig. 2B),
corresponding to the CTxB monomeric and pentameric struc-
tures, respectively.
Kinetics of serum IgG and IgA after oral immunization with
rHBc VLPs. To evaluate the potential of the full-length rHBc
as an oral immunogen, 50 g of the protein in PBS (without
adjuvant) was orally administered to six BALB/c mice on days
0, 13, 24, and 48. Blood samples were taken, and serum IgG
and IgA antibody responses were monitored by ELISA on days
0, 16, 42, 62, 72, and 106. An HBc-specific serum IgG response
could be detected 2 weeks after the first immunization and
continuously increased until day 62 (Fig. 3). At this time point,
IgG antibodies could be detected in sera of all immunized mice
at dilutions between 1/50,000 and 1/250,000. The IgG titers
remained at the same level for at least another 6 weeks after
the last immunization. HBc-specific serum IgA responses
could be detected from day 16 after the first gavage, and these
responses increased until day 106 (Fig. 4). At the end of the
experiment, all mice showed HBc-specific IgA reactivity at a
dilution of 1/50,000, the highest dilution tested.
Comparison of serum IgG levels and IgG subclasses after
oral and parenteral immunization with HBc VLPs. To deter-
mine the nature of the induced immune responses, HBc-specific
IgG subclasses of the pooled serum samples were characterized
by ELISA 2 weeks after the last oral or i.p. administration of the
HBc VLPs. Pooled serum samples were considered to be reactive
when the measured absorbance at 492 nm is two and a half times
higher than the negative-control absorbance at the same dilution.
The predominant subclass induced following oral delivery of the
HBc VLP was the IgG2a subtype (Fig. 5A). HBc-reactive serum
IgG2a antibodies could still be detected at dilutions up to
1/100,000. Serum HBc-specific IgG1 and IgG2b responses were
weaker (detectable up to dilutions of 1/5,000), and no IgG3 an-
tibodies were seen.
Following i.p. injection with the HBc VLP, all IgG subclasses
were present (Fig. 5B) in the sera of immunized mice. High
levels of HBc-specific IgG2a and IgG1 antibodies could be
demonstrated (detectable up to dilutions of 1/1,000,000), while
levels of IgG3 and IgG2b were lower. Although high levels of
HBc-specific antibodies can be detected after oral vaccination,
the HBc-specific humoral response induced after i.p. immuni-
zation is at least 10 times stronger (Fig. 6).
Comparison of serum IgG levels and subclasses after oral
immunization with HBc VLP and CTxB. Two weeks after the
last oral administration of rCTxB, pooled serum fractions were
analyzed for CTxB-specific IgG subclasses. The humoral re-
sponse induced by orally delivered CTxB appeared to be
mainly composed of the production of antibodies of the IgG1
isotype (Fig. 5C). Antibodies of the IgG1 isotype could be
detected in dilutions of up to 1/500,000. No antigen-specific
FIG. 2. (A) Purified rCTxB analyzed on a 15% SDS-PAGE gel
stained with CBB. Lane 1, LMW protein mixture (Amersham Bio-
sciences); lane 2, purified CTxB samples boiled in loading dye with
2-mercopto-ethanol. A monomeric protein band appears at 13 kDa.
Lane 3, nonboiled, purified CTxB samples loaded in 2-mercoptoetha-
nol free loading dye. A pentameric protein band appears at 50 kDa.
(B) Western blot analysis of the purified CTxB samples. Lane 2, CTxB
monomer at 13 kDa in a loading dye with -mercapto; lane 3, CTxB
pentamer at 50 kDa in a loading dye without -mercapto (sample not
boiled).
FIG. 3. Kinetics of serum IgG antibody response of BALB/c mice
after oral immunization with 50 g rHBc VLPs in PBS without any
adjuvant. The y axis shows the geometric mean titer (GMT) of the
antibody dilution at which an antigen-specific response was detected.
The x axis shows the days on which samples were taken after oral
immunization. The VLPs were orally given on days 0, 13, 24, and 48.
The error bars show the standard deviations of the mean. On day 16,
the sera of two out of the six orally immunized mice were not HBc
reactive on the lowest tested dilution (1/5,000); therefore, no negative
standard deviation could be shown on this logarithmic scale.
FIG. 4. Kinetics of serum IgA antibody response of BALB/c mice
after oral immunization with 50 g rHBc VLPs in PBS without any
adjuvant. The y axis shows the geometric mean titer (GMT) of the
antibody dilution at which an antigen-specific response was detected.
The x axis shows the days on which samples were taken after oral
immunization. The error bars show the standard deviations of the
mean. On day 106, in the sera of all orally immunized mice HBc-
specific IgA antibodies could still be detected at the highest dilution
tested (1/25,000).
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IgA antibodies could be detected after oral vaccination with
rCTxB.
DISCUSSION
When administered parenterally or nasally, VLPs have
proven to be highly immunogenic and capable of inducing a
protective immune response, even against integrated epitopes.
Lobaina et al. (37) showed that orally administered HBc VLPs
can induce a systemic humoral response following sublingual
and oral immunization of 5 g proteins. From our data, it can
be concluded that four doses of 50 g orally administered HBc
VLPs induce a strong humoral response of a potentially pro-
tective level as HBcAg-specific antibodies could still be de-
tected at a dilution of 1/100,000. Moreover, this induction
occurs even in the absence of any oral delivery system (as
liposomes) or oral adjuvant (such as CTxB). Also, immuno-
modulating lipopolysaccharide and encapsidated RNA were
restrained in the administered preparations. The induced sys-
temic humoral response is at least 10 times higher than that
induced by other orally administered VLPs (Fig. 6). Consider-
ing that immune responses against integrated epitopes are
generally weaker, the HBc particle vaccine might be the most
suitable VLP for use as carrier molecule in oral vaccination
strategies, capable of inducing sufficiently high antibody titers
against integrated epitopes. The detection of serum HBc struc-
ture-specific antibodies following oral administration proved
that the capsid structure and antigenicity of HBc were, at least
partially, conserved during passage through the gastrointesti-
nal tract. This is most likely due to the extreme pH resistance
of the VLPs and their capacity to reassemble after denatur-
ation (3, 49).
Furthermore, de Aizpurua and Russell-Jones (12) showed
that several types of antigens, especially lectins, could induce
systemic responses after oral delivery using normal dosage and
not inducing systemic tolerance. The involvement of specific
glycoconjugates in the interaction and uptake of oral patho-
gens, antibodies, and vaccine antigens by M cells in mice has
already been shown (19).
Recently, it was also proposed that C-terminal protamine-
like domains of the HBc have a specific role in guiding the
binding of capsids to host cells through interaction with mem-
brane heparan sulfate proteoglycans (8, 66). These proteogly-
cans are present on the surfaces of mucosal cells, B cells,
macrophages, and dendritic cells. Therefore, we suggest that
following oral vaccination heparan sulfates might be of partic-
ular importance, functioning as membrane receptors to facili-
tate transcytosis by M cells and uptake by other antigen-pre-
senting cells associated with the gut-associated lymphoid
tissue. In that respect, Milich and coworkers (44) reported on
the importance of B cells in antigen presentation and concom-
itant induction of an immune response following HBc admin-
istration in an in vivo mouse model. Nevertheless, the impor-
tance of specific glycoconjugates in the uptake of oral
pathogen antigens should not be underestimated, and there is,
in addition, no evidence for such a T-cell-independent B-cell
response in humans (65).
Furthermore, the protamine-like C-terminal domain of the
HBc protein appears of particular interest in conferring full
protection after immunization. De Filette et al. (13) showed
that after i.p. administration of the M2e epitope, integrated in
the N-terminal loop of a C-terminal-truncated HBc VLP, only
partial protection against influenza was induced. In contrast,
immunization with the epitope integrated in particles induced
complete protection, and this was correlated with a high IgG2a
FIG. 5. IgG subclasses (2 weeks after the last immunization) of
pooled sera from BALB/c mice immunized orally with 50 g rHBc
particles (A), i.p. with 10 g rHBc particles (B), and orally with 50 g
rCTxB (C). The y axis shows the antibody dilution at which an antigen-
specific response was detected. The x axis shows the analyzed IgG
subtypes.
FIG. 6. Absorbance values of pooled BALB/c sera analyzed for
their HBc-specific IgG levels at a dilution of 1/40,000. Pooled sera were
examined 2 weeks after the last immunization with either 50 g orally
administered rHBc particles or 10 g i.p. injected rHBc VLPs. The y
axis shows the absorbance at 490 nm, while the analyzed mouse groups
are represented on the x axis.
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level (14). Although it is assumed that the protamine domain
is easily truncated following proteolytic treatment, it might be
possible that some intact particles reach the mucosal surfaces
and establish a binding interaction with the mucosal surfaces
that facilitates internalization.
The nature of the induced immune response was determined
because it has been stated that there is a correlation between
the antigen-induced isotypes and their protective efficiency
(50). Antibodies of the IgG2a subtype are often induced fol-
lowing administration of viral antigens (10, 70) and are be-
lieved to be most effective in antibody-dependent protective
immunity (14, 40). Therefore, the isotypes of the induced IgG
response in all immunized mouse groups were determined.
The predominant IgG subtype after oral administration of the
HBc VLP was the IgG2a isotype, indicating a Th1 response.
Th1 lymphocytes are specialized in the production of gamma
interferon and are essential in the control of intracellular
pathogens, such as respiratory syncytial virus (52), measles
virus (29), agents of malaria (7), mycobacteria that cause tu-
berculosis (60), and human immunodeficiency virus (41). After
i.p. immunization with rHBc VLPs, we could detect high levels
of both IgG1 and IgG2a antibodies, pointing to a mixed Th1/
Th2 response. Mixed Th1/Th2 responses are often induced
after immunization with antigens of a polymeric nature (e.g.,
that of a repetitive and spatially ordered array of the same
epitope) (67). Mazumdar et al. (42) showed that following
vaccination against Leishmania, a mixed Th1/Th2 response is
induced, which instructs a protective Th1 response after chal-
lenge.
The HBc-specific antibody levels produced after oral immu-
nization are 10-fold lower than those obtained following i.p.
injection of the VLP, even though the orally delivered antigen
dose is 5 times higher than that which we administered i.p.
These lower antibody titers are probably due to proteolytic
degradation of the orally administered antigen. Oral immuni-
zation with higher doses of the antigen does not induce higher
serum antibody titers but might even induce oral tolerance (18,
61). Reduction in the dose by protection against proteolytic
degradation can be obtained by antigen encapsulation through
layering in polymethacrylates and skim milk (26), by the use of
oral adjuvants, or by administration of recombinant protein
expressed in edible plant parts (surrounded by the cellulose
cell wall) (for reviews, see references 20, 33, 59, and 62).
Oral immunization is enjoying great public interest in devel-
oping and Western countries, because it offers many advan-
tages over parenteral immunization. Oral immunogens are
easy to deliver, avoid nosocomial infections, reduce the need
for specialized medical assistance, and are thus potentially
useful for mass immunization (22). Expression of VLPs in
edible plant parts can reduce antigen production costs and
avoid the need for expensive and time-consuming purification
protocols. It has been shown that after freeze or air drying of
Norwalk VLPs expressed in tomato fruits, specific IgG and IgA
responses could still be induced in mice fed with these prepa-
rations (25, 72). Moreover, the corn-expressed B subunit of
heat-labile toxin, the S glycoprotein of transmissible gastroen-
teritis, and the lettuce-expressed measles virus hemagglutinin
protein have all been shown to be stable for at least 1 year,
even when stored at ambient temperatures (34, 69). This sug-
gests the potential for accessibility and use of these vaccines in
developing countries, as cold chains are not required for anti-
gen preservation.
We compared the HBc-induced antibody levels and isotypes
with those induced after oral immunization with CTxB. To-
gether with the similar E. coli heat-labile enterotoxin, CTx is
one of the most commonly used carrier and adjuvant molecules
in mucosal vaccination strategies, capable of inducing serum
IgG antibody responses (11). Its excellent carrier capacities
result from facilitating protein uptake upon binding on the
glycosphingolipid GM1 ganglioside (51), present on virtually
all cells, including immune cells. Our results (Fig. 5C) are in
agreement with those of Marinaro et al. (39), who showed that
cholera toxin especially induces a Th2 immune response asso-
ciated with high titers of IgG1 isotype antibodies. This con-
firms the modulating nature of the CTxB molecule in T-helper-
cell differentiation and activity, resulting in Th2 stimulation.
For infections with Tricuris muris and Ascaris, triggering such a
Th2 response is most beneficial (27). The shift toward a Th2
response is also important when gene fusions with the CTxB
subunit are used to induce peripheral tolerance to the coupled
antigen, an application needed in order to prevent autoim-
mune diseases (24, 33). After oral vaccination with rCTxB, no
IgA levels could be measured in the serum. Similarly, Blan-
chard et al. (4) could not detect antigen-specific IgA following
immunization with an antigen that was genetically coupled to
the CTxB toxin. These authors suggested that CTxB is acting
solely as a carrier molecule and not as an adjuvant in this
system.
In summary, our observation that the HBc VLP induces a
strong serum humoral response following oral immunization
suggests the high potential of the HBc VLP for use as a carrier
in oral vaccination strategies. The Th1-biased response can be
of particular interest where the HBc is used as a carrier vehicle
for vaccination strategies against viral and parasitic infections,
such as, e.g., malaria, tuberculosis, and leishmaniasis. These
are all infections thriving in tropical, developing regions where
needle-free, oral mass immunization can be of particular im-
portance.
ACKNOWLEDGMENTS
We thank Paulo Lee Ho (Centro de Biotecnologia, Instituto Butan-
tan, Sa˜o Paulo, Brazil) for kindly providing the ctxB gene, designed
according to the codon usage of E. coli. We also gratefully acknowl-
edge E. Biebaut and A. Geldmeyer for technical assistance and I. Van
Dyck for help with the figures. We also thank G. Horvath (University
of Antwerp) for his help with the fermentation and A. Durieux of the
Institut Meurice (Anderlecht) for the use of their fermentation infra-
structure. We are grateful to M. Jansen (University College Cork) for
critical reading the manuscript and for helpful comments.
This work was supported by a NOI/BOF grant from the University
of Antwerp (K. Broos). M. Janssens and I. De Goeyse are both Re-
search Assistants of the Fund for Scientific Research Flanders (FWO,
Belgium).
REFERENCES
1. Areas, A. P., M. L. Oliveira, C. R. Ramos, M. E. Sbrogio-Almeida, I. Raw,
and P. L. Ho. 2002. Synthesis of cholera toxin B subunit gene: cloning and
expression of a functional 6Xhistagged protein in Escherichia coli. Protein
Expr. Purif. 25:481–487.
2. Ball, J. M., M. E. Hardy, R. L. Atmar, M. E. Conner, and M. K. Estes. 1998.
Oral immunization with recombinant Norwalk virus-like particles induces a
systemic and mucosal immune response in mice. J. Virol. 72:1345–1353.
3. Birnbaum, F., and M. Nassal. 1990. Hepatitis B virus nucleocapsid assembly:
primary structure requirements in the core protein. J. Virol. 64:3319–3330.
856 BROOS ET AL. CLIN. VACCINE IMMUNOL.
 at Universiteitsbibliotheek G
ent on M
arch 18, 2009 
cdli.asm
.org
D
ow
nloaded from
 
4. Blanchard, T. G., N. Lycke, S. J. Czinn, and J. G. Nedrud. 1998. Recombi-
nant cholera toxin B subunit is not an effective mucosal adjuvant for oral
immunization of mice against Helicobacter felis. Immunology 94:22–27.
5. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye bind-
ing. Anal. Biochem. 72:248–254.
6. Broos, K., P. Vanlandschoot, M. Maras, J. Robbens, G. Leroux-Roels, and Y.
Guisez. 2007. Expression, purification and characterization of full-length
RNA-free hepatitis B core particles. Protein Expr. Purif. 54:30–37.
7. Bruna-Romero, O., C. D. Rocha, M. Tsuji, and R. T. Gazzinelli. 2004.
Enhanced protective immunity against malaria by vaccination with a recom-
binant adenovirus encoding the circumsporozoite protein of Plasmodium
lacking the GPI-anchoring motif. Vaccine 22:3575–3584.
8. Cooper, A., G. Tal, O. Lider, and Y. Shaul. 2005. Cytokine induction by
hepatitis B virus capsid in macrophages is facilitated by membrane heparin
sulfate and involves TLR2. J. Immunol. 175:3165–3176.
9. Cooper, A., and Y. Shaul. 2006. Clathrin-mediated endocytosis and lysoso-
mal cleavage of hepatitis B virus capsid-like core particles. J. Biol. Chem.
281:16563–16569.
10. Coutelier, J. P., J. T. van der Logt, F. W. Heessen, G. Warnier, and J. Van
Snick. 1987. IgG2a restriction of murine antibodies elicited by viral infec-
tions. J. Exp. Med. 165:64–69.
11. Cox, E., F. Verdonck, D. Vanrompay, and B. Goddeeris. 2006. Adjuvants
modulating mucosal immune responses or directing systemic responses to-
wards the mucosa. Vet. Res. 37:511–539.
12. de Aizpurua, H. J., and G. J. Russell-Jones. 1988. Oral vaccination. Identi-
fication of classes of proteins that provoke an immune response upon oral
feeding. J. Exp. Med. 167:440–451.
13. De Filette, M., W. Min Jou, A. Birkett, K. Lyons, B. Schultz, A. Tonkyro, S.
Resch, and W. Fiers. 2005. Universal influenza A vaccine: optimization of
M2-based constructs. Virology 337:149–161.
14. Fiers, W., M. De Filette, A. Birkett, S. Neirynck, and W. Min Jou. 2004. A
“universal” human influenza A vaccine. Virus Res. 103:173–176.
15. Fifis, T., A. Gamvrellis, B. Crimeen-Irwin, G. A. Pietersz, J. Li, P. L. Mottram,
I. F. McKenzie, and M. Plebanski. 2004. Size-dependent immunogenicity: ther-
apeutic and protective properties of nano-vaccines against tumors. J. Immunol.
173:3148–3154.
16. Fingerut, E., B. Gutter, R. Meir, D. Eliahoo, and J. Pitcovski. 2005. Vaccine
and adjuvant activity of recombinant subunit B of E. coli enterotoxin pro-
duced in yeast. Vaccine 23:4685–4696.
17. Gamvrellis, A., D. Leong, J. C. Hanley, S. D. Xiang, P. Mottram, and M.
Plebanski. 2004. Vaccines that facilitate antigen entry into dendritic cells.
Immunol. Cell Biol. 82:506–516.
18. Garside, P., and A. M. Mowat. 2001. Oral tolerance. Semin. Immunol.
13:177–185.
19. Giannasca, P. J., K. T. Giannasca, P. Falk, J. I. Gordon, and M. R. Neutra.
1994. Regional differences in glycoconjugates of intestinal M cells in mice:
potential targets for mucosal vaccines. Am. J. Physiol. 267:G1108–G1121.
20. Giddings, G., G. Allison, D. Brooks, and A. Carter. 2000. Transgenic plants
as factories for biopharmaceuticals. Nat. Biotechnol. 18:1151–1155.
21. Giroglou, T., L. Florin, F. Schafer, R. E. Streeck, and M. Sapp. 2001. Human
papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:
1565–1570.
22. Giudice, E. L., and J. D. Campbell. 2006. Needle-free vaccine delivery. Adv.
Drug Deliv. Rev. 58:68–89.
23. Guisez, Y., I. Fache, L. A. Campfield, F. J. Smith, A. Farid, G. Plaetinck, J.
Van der Heyden, J. Tavernier, W. Fiers, P. Burn, and R. Devos. 1998.
Efficient secretion of biologically active recombinant OB protein (leptin) in
Escherichia coli, purification from the periplasm and characterization. Pro-
tein Expr. Purif. 12:249–258.
24. Holmgren, J., J. Adamsson, F. Anjue`re, J. Clemens, C. Czerkinsky, K.
Eriksson, C. F. Flach, A. George-Chandy, A. M. Harandi, M. Lebens, T.
Lehner, M. Lindblad, E. Nygren, S. Raghavan, J. Sanchez, M. Stanford, J.
B Sun, A. M. Svennerholm, and S. Tengvall. 2005. Mucosal adjuvants and
anti-infection and anti-immunopathology vaccines based on cholera toxin,
cholera toxin B subunit and CpG DNA. Immunol. Lett. 97:181–188.
25. Huang, Z., G. Elkin, B. J. Maloney, N. Beuhner, C. J. Arntzen, Y. Thanavala,
and H. S. Mason. 2005. Virus-like particle expression and assembly in plants:
hepatitis B and Norwalk viruses. Vaccine 23:1851–1858.
26. Huyghebaert, N., A. Vermeire, P. Rottiers, E. Remaut, and J. P. Remon.
2005. Development of an enteric-coated, layered multi-particulate formula-
tion for ileal delivery of viable recombinant Lactococcus lactis. Eur. J. Pharm.
Biopharm. 61:134–141.
27. Ismail, N., and P. A. Bretscher. 1999. The Th1/Th2 nature of concurrent
immune responses to unrelated antigens can be independent. J. Immunol.
163:4842–4850.
28. Koschel, M., R. Thomssen, and V. Bruss. 1999. Extensive mutagenesis of the
hepatitis B virus core gene and mapping of mutations that allow capsid
formation. J. Virol. 73:2153–2160.
29. Kovarik, J., M. Gaillard, X. Martinez, P. Bozzotti, P. H. Lambert, T. F. Wild,
and C. A. Siegrist. 2001. Induction of adult-like antibody, Th1, and CTL
responses to measles hemagglutinin by early life murine immunization with
an attenuated vaccinia-derived NYVAC(K1L) viral vector. Virology 285:
12–20.
30. Kratz, P. A., B. Bo¨ttcher, and M. Nassal. 1999. Native display of complete
foreign protein domains on the surface of hepatitis B virus capsids. Proc.
Natl. Acad. Sci. USA 96:1915–1920.
31. Lachmann, S., H. Meisel, C. Muselmann, D. Koletzki, H. R. Gelderblom, G.
Borisova, D. H. Kruger, P. Pumpens, and R. Ulrich. 1999. Characterization
of potential insertion sites in the core antigen of hepatitis B virus by the use
of a short-sized model epitope. Intervirology 42:51–56.
32. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of
the head of bacteriophage T4. Nature 227:680–685.
33. Lal, P., V. G. Ramachandran, R. Goyal, and R. Sharma. 2007. Edible
vaccines: current status and future. Indian J. Med. Microbiol. 25:93–102.
34. Lamphear, B. J., S. J. Streatfield, J. M. Jilka, C. A. Brooks, D. K. Barker,
D. D. Turner, D. E. Delaney, M. Garcia, B. Wiggins, S. L. Woodard, E. E.
Hood, I. R. Tizard, B. Lawhorn, and J. A. Howard. 2002. Delivery of subunit
vaccines in maize seed. J. Control. Release 85:169–180.
35. Lesieur, C., M. J. Cliff, R. Carter, R. F. James, A. R. Clarke, and T. R. Hirst.
2002. A kinetic model of intermediate formation during assembly of cholera
toxin B-subunit pentamers. J. Biol. Chem. 277:16697–16704.
36. Li, T., N. Takeda, and T. Miyamura. 2001. Oral administration of hepatitis
E virus-like particles induces a systemic and mucosal immune response in
mice. Vaccine 19:3476–3484.
37. Lobaina, Y., D. Garcia, N. Abreu, V. Muzio, and J. C. Aguilar. 2003. Mucosal
immunogenicity of the hepatitis B core antigen. Biochem. Biophys. Res.
Commun. 300:745–750.
38. Ludwig, D. S., R. K. Holmes, and G. K. Schoolnik. 1985. Chemical and
immunochemical studies on the receptor binding domain of cholera toxin B
subunit. J. Biol. Chem. 260:12528–12534.
39. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka,
N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, K. Fujihashi, and
J. R. McGhee. 1995. Mucosal adjuvant effect of cholera toxin in mice results
from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621–
4629.
40. Markine-Goriaynoff, D., and J. P. Coutelier. 2002. Increased efficacy of the
immunoglobulin G2a subclass in antibody-mediated protection against lac-
tate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed
with switch mutants. J. Virol. 76:432–435.
41. Mascarell, L., C. Fayolle, C. Bauche, D. Ladant, and C. Leclerc. 2005.
Induction of neutralizing antibodies and Th1-polarized and CD4-indepen-
dent CD8 T-cell responses following delivery of human immunodeficiency
virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella
pertussis. J. Virol. 79:9872–9884.
42. Mazumdar, T., K. Anam, and N. Ali. 2004. A mixed Th1/Th2 response
elicited by a liposomal formulation of Leishmania vaccine instructs Th1
responses and resistance to Leishmania donovani in susceptible BALB/c
mice. Vaccine 22:1162–1171.
43. Milich, D. R., J. Hughes, J. Jones, M. Sa¨llberg, and T. R. Phillips. 2001.
Conversion of poorly immunogenic malaria repeat sequences into a highly
immunogenic vaccine candidate. Vaccine 20:771–788.
44. Milich, D. R., M. Chen, F. Scho¨del, D. L. Peterson, J. E. Jones, and J. L.
Hughes. 1997. Role of B cells in antigen presentation of the hepatitis B core.
Proc. Natl. Acad. Sci. USA 94:14648–14653.
45. Milich, D. R., D. L. Peterson, J. Zheng, J. L. Hughes, R. Wirtz, and F.
Schodel. 1995. The hepatitis nucleocapsid as a vaccine carrier moiety. Ann.
N. Y. Acad. Sci. 754:187–201.
46. Milich, D. R., and A. McLachlan. 1986. The nucleocapsid of hepatitis B virus
is both a T-cell-independent and a T-cell-dependent antigen. Science 234:
1398–1401.
47. Missiakas, D., J. M. Betton, and S. Raina. 1996. New components of protein
folding in extracytoplasmic compartments of Escherichia coli SurA, FkpA
and Skp/OmpH. Mol. Microbiol. 21:871–884.
48. Neirynck, S., T. Deroo, X. Saelens, P. Vanlandschoot, W. Min Jou, and W.
Fiers. 1999. A universal influenza A vaccine based on the extracellular
domain of the M2 protein. Nat. Med. 5:1157–1163.
49. Newman, M., F. M. Suk, M. Cajimat, P. K. Chua, and C. Shik. 2003. Stability
and morphology comparisons of self-assembled virus-like particles from
wild-type and mutant human hepatitis B virus capsid proteins. J. Virol.
77:12950–12960.
50. Perez Filgueira, D. M., A. Berinstein, E. Smitsaart, M. V. Borca, and A. M.
Sadir. 1995. Isotype profiles induced in Balb/c mice during foot and mouth
disease (FMD) virus infection or immunization with different FMD vaccine
formulations. Vaccine 13:953–960.
51. Petersen, J. S., S. Bregenholt, V. Apostolopolous, D. Homann, T. Wolfe, A.
Hughes, K. De Jongh, M. Wang, T. Dyrberg, and M. G. Von Herrath. 2003.
Coupling of oral human or porcine insulin to the B subunit of cholera toxin
(CTB) overcomes critical antigenic differences for prevention of type I dia-
betes. Clin. Exp. Immunol. 134:38–45.
52. Plotnicky-Gilquin, H., D. Cyblat-Chanal, J. P. Aubry, T. Champion, A. Beck,
T. Nguyen, J. Y. Bonnefoy, and N. Corvaia. 2002. Gamma interferon-depen-
dent protection of the mouse upper respiratory tract following parenteral
VOL. 15, 2008 ORAL IMMUNIZATION WITH HBc VLPs 857
 at Universiteitsbibliotheek G
ent on M
arch 18, 2009 
cdli.asm
.org
D
ow
nloaded from
 
immunization with a respiratory syncytial virus G protein fragment. J. Virol.
76:10203–10210.
53. Pumpens, P., and E. Grens. 2001. HBV core particles as a carrier for B cell/T
cell epitopes. Intervirology 44:98–114.
54. Pumpens, P., G. P. Borisova, R. A. Crowther, and E. Grens. 1995. Hepatitis
B virus core particles as epitope carriers. Intervirology 38:63–74.
55. Rose, R. C., C. Lane, S. Wilson, J. A. Suzich, E. Rybicki, and A. L. Williamson.
1999. Oral vaccination of mice with human papillomavirus virus-like particles
induces systemic virus-neutralizing antibodies. Vaccine 17:2129–2135.
56. Schodel, F., D. Peterson, D. R. Milich, Y. Charoenvit, J. Sadoff, and R. Wirtz.
1997. Immunization with hybrid hepatitis B virus core particles carrying
circumsporozoite antigen epitopes protects mice against Plasmodium yoelii
challenge. Behring Inst. Mitt. 98:114–119.
57. Schodel, F., R. Wirtz, D. Peterson, J. Hughes, R. Warren, J. Sadoff, and D.
Milich. 1994. Immunity to malaria elicited by hybrid hepatitis B virus core
particles carrying circumsporozoite protein epitopes. J. Exp. Med. 180:1037–
1046.
58. Schonberger, O., T. R. Hirst, and O. Pines. 1991. Targeting and assembly of
an oligomeric bacterial enterotoxoid in the endoplasmic reticulum of Sac-
charomyces cerevisiae. Mol. Microbiol. 5:2663–2671.
59. Streatfield, S. J., and J. A. Howard. 2003. Plant production systems for
vaccines. Expert Rev. Vaccines 2:763–775.
60. Surcel, H. M., M. Troye-Blomberg, S. Paulie, G. Andersson, C. Moreno, G.
Pasvol, and J. Ivanyi. 1994. Th1/Th2 profiles in tuberculosis, based upon
proliferation and the cytokine response of blood lymphocytes to mycobac-
terial antigens. Immunology 81:171–176.
61. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, and M. K.
Estes. 2003. Humoral, mucosal, and cellular immune responses to oral Nor-
walk virus-like particles in volunteers. Clin. Immunol. 108:241–247.
62. Tacket, C. O., and H. S. Mason. 1999. A review of oral vaccination with
transgenic vegetables. Microbes Infect. 1:777–783.
63. Reference deleted.
64. Ulrich, R., A. Lundkvist, H. Meisel, D. Koletzki, K. B. Sjolander, H. R.
Gelderblom, G. Borisova, P. Schnitzler, G. Darai, and D. H. Kruger. 1998.
Chimaeric HBV core particles carrying a defined segment of Puumala han-
tavirus nucleocapsid protein evoke protective immunity in an animal model.
Vaccine 16:272–280.
65. Vanlandschoot, P., F. Van Houtte, B. Serruys, and G. Leroux-Roels. 2007.
Contamination of a recombinant hepatitis B virus nucleocapsid preparation
with a human B-cell activator. J. Virol. 81:2535–2536.
66. Vanlandschoot, P., F. Van Houtte, B. Serruys, and G. Leroux-Roels. 2005.
The arginine-rich carboxy-terminal domain of the hepatitis B virus core
protein mediates attachment of the nucleocapsids to cell-surface-expressed
heparan sulphate. J. Gen. Virol. 86:75–84.
67. Velikovsky, C. A., F. A. Goldbaum, J. Cassataro, S. Estein, R. A. Bowden, L.
Bruno, C. A. Fossati, and G. H. Giambartolomei. 2003. Brucella lumazine
synthase elicits a mixed Th1-Th2 immune response and reduces infection in
mice challenged with Brucella abortus 544 independently of the adjuvant
formulation used. Infect. Immun. 71:5750–5755.
68. Wardrop, R. M., and C. C. Whitacre. 1999. Oral tolerance in the treatment
of inflammatory autoimmune diseases. Inflamm. Res. 48:106–119.
69. Webster, D. E., S. D. Smith, R. J. Pickering, R. A. Strugnell, I. B. Dry, and
S. L. Wesselingh. 2006. Measles virus hemagglutinin protein expressed in
transgenic lettuce induces neutralising antibodies in mice following mucosal
vaccination. Vaccine 24:3538–3544.
70. Yao, Q. 2003. Enhancement of mucosal immune responses by chimeric
influenza HA/SHIV virus-like particles. Res. Initiat. Treat. Action 8:20–21.
71. Yu, J., H. Webb, and T. R. Hirst. 1992. A homologue of the Escherichia coli
DsbA protein involved in disulphide bond formation is required for entero-
toxin biogenesis in Vibrio cholerae. Mol. Microbiol. 6:1949–1958.
72. Zhang, X., N. A. Buehner, A. M. Hutson, M. K. Estes, and H. S. Mason.
2006. Tomato is a highly effective vehicle for expression and oral immuni-
zation with Norwalk virus capsid protein. Plant Biotechnol. J. 4:419–432.
858 BROOS ET AL. CLIN. VACCINE IMMUNOL.
 at Universiteitsbibliotheek G
ent on M
arch 18, 2009 
cdli.asm
.org
D
ow
nloaded from
 
